Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...

In recent decades, the incidence of some hematological malignancies (HMs), such as acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML), has decreased, while the incidence of others ...

The fine chemical sector in Europe is witnessing a notable transformation, primarily fueled by the pharmaceutical industry ...

The Hematological Genetics lab is led by Drs Outi Kilpivaara (geneticist) and Ulla Wartiovaara-Kautto (clinical hematologist). Our research stems from the intriguing curiosity towards mechanisms of ...

CAR T cell therapy has revolutionized cancer treatment, achieving significant success in hematological cancers through ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Three patients also had a complete remission but without higher white blood cell counts, known as a complete remission with ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

Good day, and welcome to the Bionano third quarter 2024 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...